A client’s novel drug program, whose cell lines were developed on Great Bay Bio’s AlfaCell Platform, has recently secured FDA Fast Track designation. The out-licensed pipeline has smoothly advanced to Phase II clinical trials, with the first patient dosed!

▲ AlfaCell Platform Powers Client’s Out-Licensed Pipeline into Phase II Clinical Trials

FDA Fast Track Designation: AlfaCell Accelerates Global Regulatory Filings

As the world’s first commercial site-specific integration cell line construction platform, AlfaCell completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA) in April 2023, holding the distinction of being the first commercial site-specific integration cell line platform globally to finish FDA DMF registration (No. 038272）.

▲ AlfaCell Platform Has Completed FDA Drug Master File (DMF) Filing

Clients utilizing products generated via the AlfaCell Platform may directly reference this DMF number in regulatory dossiers submitted to the FDA and other authorities for new drug registration. This drastically cuts review and assessment timelines, streamlines filing packages, and expedites the overall regulatory submission process for pharmaceutical assets.

The successful progression of the client’s out-licensed pipeline to Phase II trials further validates that AlfaCell’s cell line development system fully aligns with world-leading pharmaceutical standards. It delivers compliant, robust, high-performance cell line technologies for biopharma enterprises worldwide, significantly shortening global clinical development timelines and accelerating the commercialization of innovative therapeutics.

Diverse Novel Drug Portfolio with Stable Titers of 4–16 g/L

AlfaCell has delivered numerous projects for biotech clients across China and overseas, covering mAbs, bispecific antibodies, multispecific antibodies, nanobodies, fusion proteins, ADCs and hard-to-express proteins. The platform delivers stable expression titers ranging from 4 to 16 g/L with mismatch rates generally below 20%. It supports high-titer, high-quality cell line development for both early-stage lab screening and large-scale industrial manufacturing, balancing robust R&D efficiency and favorable production costs.

▲ AlfaCell Platform Has Supported Cell Line Generation for 100 Product Candidates with Stable Titers of 4–16 g/L

Breakthrough Biosimilar Titers Reaching a Maximum of 25.3 g/L

Beyond novel therapeutics, AlfaCell empowers biosimilar R&D for clients across Taiwan (China), South Korea and other global regions, delivering exceptional expression yields for multiple product candidates.

Several flagship mAb biosimilars achieved outstanding titers in unoptimized shake flasks:

Ipilimumab: 25.3 g/L

Ozoralizumab: 16.85 g/L

Dupilumab: 10.2 g/L

Note: Data obtained from unoptimized shake flask cultures

Critical quality attributes highly comparable to the reference product, and cell line stability meets global regulatory requirements for clinical filings. The platform covers mainstream targets and molecular formats, including CTLA-4, TNFα, IL-4Rα/IL-13, VEGF/ANG2, PD-1, HSA fusion proteins and bispecific antibodies.

▲ All data generated from unoptimized shake flask studies on AlfaCell Platform; all cell lines have completed Research Cell Bank (RCB) construction and are ready for clinical filing

Leveraging AlfaCell’s industry-leading high-titer output and full regulatory compliance, clients worldwide are advancing parallel pipelines of novel drugs and biosimilars. AlfaCell’s efficient, compliant and reliable cell line development capabilities equip partners with solid core advantages to advance overseas clinical programs and capture global market share.

About the AlfaCell Platform

AlfaCell combines fluorescent labeling technology with site-specific integration. Through visual screening, target genes are precisely inserted into highly active genomic loci that deliver stable, high-level protein expression and superior quality. Integrated with high-throughput sorting, detection and clonality analysis instruments including FACS, VIPS and Octet, the platform enables streamlined process development. It delivers high-yield, stable cell lines in just 1.5 months and enables early prediction of product quality within 1 month, efficiently generating cell lines scalable for industrial manufacturing.

As the world’s first commercial site-specific integration cell line construction platform, AlfaCell holds an FDA DMF filing, ISO 9001:2015 quality management system certification and completed FTO freedom-to-operate reports. A global patent portfolio has been pre-established covering plasmids, integration loci and AI technologies for the platform’s site-specific integration workflows.

AlfaCell has delivered hundreds of projects to biopharma clients. Multiple partners have obtained Clinical Trial Application (CTA) approvals from China’s National Medical Products Administration (NMPA) and FDA IND (Investigational New Drug) clearance, advancing their assets into Phase I and Phase II clinical trials successively.